|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
4.890 +0.070 (+1.452%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 131,866,817 | 2.542% | 257,673,256 | 244,703,884 | 218,182,994 | 193,611,454 |
| Cost of Sales | (110,357,203) | 2.501% | (216,984,387) | (206,366,398) | (184,563,943) | (164,684,722) |
| Gross Profit | 21,509,614 | 2.752% | 40,688,869 | 38,337,486 | 33,619,051 | 28,926,732 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 113,236 | -43.032% | 368,014 | 417,106 | 332,341 | 256,395 | |
| Profit / (Loss) before Taxation | 6,415,965 | -8.943% | 10,929,922 | 9,880,227 | 8,361,081 | 6,874,689 | |
| Taxation | (1,362,328) | -9.511% | (2,526,679) | (2,105,224) | (1,703,152) | (1,439,805) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,976,355) | 1.383% | (5,052,386) | (3,920,756) | (3,157,659) | (2,353,460) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,077,282 | -20.252% | 3,350,857 | 3,854,247 | 3,500,270 | 3,081,423 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 735,003 | -8.790% | 1,600,779 | 1,798,626 | 1,732,289 | 1,647,741 |
| Depreciation & Amortisation | 1,887,553 | 15.942% | 3,356,710 | 3,164,365 | 2,558,441 | 2,307,162 |
| Directors' Emoluments | -- | -- | 8,744 | 8,088 | 11,224 | 10,977 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 33.000 | -19.512% | 53.000 | 61.000 | 56.000 | 49.056 |
| DPS (cts) | 7.200 | -- | 13.500 | 15.400 | 14.292 | 12.264 |
| Dividend Payout Ratio (%) | 21.818% | -- | 25.472% | 25.246% | 25.522% | 25.000% |
| Cash flow per share ($) | -- | -- | 2.791 | 2.475 | 1.722 | 1.671 |
| NBV per share ($) | 7.953 | -- | 7.679 | 7.315 | 6.933 | 6.635 |
| Remarks: | Real time quote last updated: 05/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,077,282 |
| %Change | -20.252% |
| EPS / (LPS) | RMB 0.330 |
| NBV Per Share (¥) | RMB 7.953 |